Since 1983, eight new AEDs have been introduced (see Table 2 below). Sadly, a recent VA study of more than 21,000 subjects aged 65 years and older revealed that 80% were being treated with ...
(NewsNation) — March 26 is Purple Day, a day dedicated to raising awareness about epilepsy worldwide. An estimated 50 million people worldwide are diagnosed with epilepsy, and seizures are the main ...
CHARLOTTESVILLE, Va. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cavion, Inc., a clinical stage biotechnology company developing novel therapeutics for neurological diseases, announced today that their first ...
Company's BMB-101 targets drug-resistant epilepsy, aiming for a multibillion-dollar market by treating patients unresponsive to standard anti-seizure medications. Company's phase 2 trial for Absence ...
Bright Minds Biosciences announces Phase 2 Clinical trial to evaluate BMB-101 in a group of drug-resistant epilepsy disorders with high unmet needs BMB-101 is a novel highly selective 5-HT2C agonist.
Myocardial infarction is significantly associated with the development of epilepsy and nonstroke vascular death in older adults, new research shows.